FDA label ladder
Semaglutide Wegovy label ladder to 2.4 mg: published ladder and modeled levels
Short answer
Semaglutide Wegovy label ladder to 2.4 mg: 0.25/0.5/1/1.7/2.4 mg weekly, 4 weeks per step (Novo Nordisk, Jun 18, 2026). The final 2.4 mg step begins in week 17. With t½ 7 days and R = 2, the modeled amount peaks at 4.28 mg-eq. As published, not a recommendation; as of Oct 19, 2026.
- Weeks per step
- 4 5 steps
- Final step
- 2.4 mg from week 17
- Modeled peak
- 4.28 mg-eq
- Accumulation R
- 2 t½ 7 d
- Weekly dose (published steps)
- Modeled amount (mg-eq)
- Stable window
| Weeks | Weekly dose | First week starts |
|---|---|---|
| 1–4 | 0.25 mg | Jan 5, 2026 |
| 5–8 | 0.5 mg | Feb 2, 2026 |
| 9–12 | 1 mg | Mar 2, 2026 |
| 13–16 | 1.7 mg | Mar 30, 2026 |
| 17 onward | 2.4 mg | Apr 27, 2026 |
Weekly modeled amounts
Download CSV
32 weeks. Highlighted rows start a new dose step. Model details: model card.
| Week | Starts | Dose mg | Peak | Trough | Average |
|---|---|---|---|---|---|
| 1 | Jan 5, 2026 | 0.25 | 0.215 | 0 | 0.165 |
| 2 | Jan 12, 2026 | 0.25 | 0.33 | 0.131 | 0.263 |
| 3 | Jan 19, 2026 | 0.25 | 0.387 | 0.197 | 0.312 |
| 4 | Jan 26, 2026 | 0.25 | 0.416 | 0.229 | 0.336 |
| 5 | Feb 2, 2026 | 0.5 | 0.645 | 0.246 | 0.513 |
| 6 | Feb 9, 2026 | 0.5 | 0.768 | 0.385 | 0.617 |
| 7 | Feb 16, 2026 | 0.5 | 0.829 | 0.455 | 0.669 |
| 8 | Feb 23, 2026 | 0.5 | 0.86 | 0.489 | 0.695 |
| 9 | Mar 2, 2026 | 1 | 1.303 | 0.507 | 1.038 |
| 10 | Mar 9, 2026 | 1 | 1.542 | 0.777 | 1.24 |
| 11 | Mar 16, 2026 | 1 | 1.662 | 0.913 | 1.342 |
| 12 | Mar 23, 2026 | 1 | 1.722 | 0.981 | 1.392 |
| 13 | Mar 30, 2026 | 1.7 | 2.35 | 1.014 | 1.879 |
| 14 | Apr 6, 2026 | 1.7 | 2.689 | 1.398 | 2.166 |
| 15 | Apr 13, 2026 | 1.7 | 2.859 | 1.59 | 2.309 |
| 16 | Apr 20, 2026 | 1.7 | 2.945 | 1.686 | 2.381 |
| 17 | Apr 27, 2026 | 2.4 | 3.584 | 1.734 | 2.878 |
| 18 | May 4, 2026 | 2.4 | 3.93 | 2.125 | 3.17 |
| 19 | May 11, 2026 | 2.4 | 4.104 | 2.32 | 3.316 |
| 20 | May 18, 2026 | 2.4 | 4.191 | 2.418 | 3.389 |
| 21 | May 25, 2026 | 2.4 | 4.235 | 2.467 | 3.426 |
| 22 | Jun 1, 2026 | 2.4 | 4.256 | 2.491 | 3.444 |
| 23 | Jun 8, 2026 | 2.4 | 4.267 | 2.504 | 3.453 |
| 24 | Jun 15, 2026 | 2.4 | 4.273 | 2.51 | 3.458 |
| 25 | Jun 22, 2026 | 2.4 | 4.275 | 2.513 | 3.46 |
| 26 | Jun 29, 2026 | 2.4 | 4.277 | 2.514 | 3.461 |
| 27 | Jul 6, 2026 | 2.4 | 4.277 | 2.515 | 3.462 |
| 28 | Jul 13, 2026 | 2.4 | 4.278 | 2.515 | 3.462 |
| 29 | Jul 20, 2026 | — | 2.6 | 1.305 | 1.879 |
| 30 | Jul 27, 2026 | — | 1.3 | 0.653 | 0.94 |
| 31 | Aug 3, 2026 | — | 0.65 | 0.326 | 0.47 |
| 32 | Aug 10, 2026 | — | 0.325 | 0.163 | 0.235 |
Sources
- WEGOVY (semaglutide) injection, for subcutaneous use; WEGOVY (semaglutide) tablets, for oral use - Full Prescribing Information (SPL, Revised 6/2026). Novo Nordisk / National Library of Medicine DailyMed, Jun 18, 2026. Accessed Oct 19, 2026.